CNS Pharmaceuticals (CNSP) investor relations material

Executive summary

• Executed a strategic pivot in 2026 to focus on building a high-value pipeline in neurology and oncology, moving away from a singular focus on glioblastoma multiforme and exploring out-licensing of legacy assets TPI 287 and Berubicin.

• Appointed a new executive team, including a new CEO, CFO, CMO, CBO, and CTO, to drive the new corporate strategy and asset acquisition.

• Neurology and oncology represent large, fast-growing markets with significant unmet medical needs and robust investment activity.

Financial highlights

• Net loss for the year ended December 31, 2025 was approximately $15.85 million, compared to $14.86 million in 2024, primarily due to increased research and development costs.

• General and administrative expenses increased to $6.21 million in 2025 from $5.61 million in 2024, mainly due to higher employee compensation and professional expenses.

• Research and development expenses rose to $9.77 million in 2025 from $9.29 million in 2024, reflecting increased spending on TPI 287 and reduced costs for Berubicin.

• Cash and cash equivalents as of December 31, 2025 were $7.2 million, with working capital of $4.0 million.

• Raised approximately $14.0 million in net proceeds from equity offerings and warrant exercises during 2025.

Outlook and guidance

• Cash on hand is expected to fund operations into the third quarter of 2026; significant additional capital will be required to execute the new strategy and expand the pipeline.

• No revenue from product sales is expected until successful development and regulatory approval of new assets.

• The company is actively seeking to in-license or acquire differentiated neurology and oncology assets with near- to mid-term value inflection points.